Table 1.
Summary of baseline characteristics of 229 mRCC patients treated with ICI with or without RASi.
| DFCI | UCSD | |||
|---|---|---|---|---|
| N (median) | % (range) | N (median) | % (range) | |
| Age at ICI start | 63 | 37-85 | 63 | 23-89 |
| Gender | ||||
| Female | 69 | 69.0 | 91 | 70.5 |
| Male | 31 | 31.0 | 38 | 29.5 |
| IMDC risk score | ||||
| Poor | 14 | 14.0 | 32 | 24.8 |
| Intermediate | 59 | 59.0 | 68 | 52.7 |
| Good | 24 | 24.0 | 29 | 22.5 |
| NA | 3 | 3.0 | 0 | 0.0 |
| Histology | ||||
| Clear cell | 89 | 89.0 | 84 | 65.1 |
| Non-clear cell | 11 | 11.0 | 45 | 34.9 |
| ICI type | ||||
| Single | 91 | 91.0 | 106 | 82.1 |
| Combination | 9 | 9.0 | 23 | 17.9 |
| Number of prior lines | ||||
| 1 | 15 | 15.0 | 51 | 39.5 |
| 2 | 46 | 46.0 | 50 | 38.8 |
| ≥3 | 39 | 39.0 | 28 | 21.7 |
| ACEi/ARB treatment | ||||
| ACEi | 23 | 23.0 | 36 | 27.9 |
| ARB | 7 | 7.0 | 24 | 18.6 |
| Neither | 70 | 70.0 | 69 | 53.5 |
Abbreviations: ACEi = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blocker; DFCI = Dana-Farber Cancer Institute; ICI = immune-checkpoint inhibitors; UCSD = University of California San Diego.